Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Vincenzo Nasca"'
Autor:
Leonardo Provenzano, Yong Xiang Gwee, Veronica Conca, Sara Lonardi, Silvia Bozzarelli, Emiliano Tamburini, Alessandro Passardi, Alberto Zaniboni, Federica Tosi, Giuseppe Aprile, Vincenzo Nasca, Alessandra Boccaccino, Margherita Ambrosini, Guglielmo Vetere, Martina Carullo, Marcello Guaglio, Luigi Battaglia, Joseph Jonathan Zhao, Daryl Kai Ann Chia, Wei Peng Yong, Patrick Tan, Jimmy So, Guowei Kim, Asim Shabbir, Chin-Ann Johnny Ong, Francesco Casella, Chiara Cremolini, Maria Bencivenga, Raghav Sundar, Filippo Pietrantonio
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Ascites is common in advanced gastrointestinal cancers with peritoneal metastases (PM) and negatively impacts patient survival. No study to date has specifically evaluated the relationship between ascites, PM and survival outcomes in meta
Externí odkaz:
https://doaj.org/article/bc9281818c7f47ceb2097603de735614
Autor:
Akihito Kawazoe, Kohei Shitara, Sara Lonardi, Filippo Pietrantonio, Samuel J Klempner, Thierry André, Massimiliano Salati, Margherita Ambrosini, Giovanni Randon, Romain Cohen, Paolo Manca, Vincenzo Nasca, Joseph Chao, Leonardo Provenzano, Yu Aoki, Steven B Maron, Riccardo Cerantola, Lorenzo Fornaro, Walter Ferrari Bravo, Filippo Ghelardi, Valerie Zhu, Darren Cowzer, Virginia Genovesi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Background Subgroup analyses of randomized trials suggest the superiority of immune checkpoint inhibitor-based therapy over chemotherapy in patients with mismatch-repair deficient (dMMR) and/or microsatellite instability-high (MSI-high) advanced gast
Externí odkaz:
https://doaj.org/article/f743b9a859bf4ca78c1d5072f84a6e85
Autor:
Vincenzo Nasca, Anna Maria Frezza, Carlo Morosi, Ciriaco Buonomenna, Antonina Parafioriti, Giorgio Zappalà, Federica Bini, Paolo Giovanni Casali, Mattia Loppini, Silvia Stacchiotti
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Giant cell tumor of the bone (GCTB) is a locally aggressive neoplasm where surgery is often curative. However, it can rarely give rise to distant metastases. Currently, the only available active therapeutic option for unresectable GCTB is denosumab,
Externí odkaz:
https://doaj.org/article/d41d6a42e618418ba3efa4ec87d4da29
Autor:
Paola Cappello, Maurizio Martini, Aldo Scarpa, Stefano Ugel, Francesco De Sanctis, Giampaolo Tortora, Emilio Bria, Vincenzo Corbo, Carmine Carbone, Geny Piro, Antonio Agostini, Pietro Delfino, Vincenzo Nasca, Francesco Spallotta, Claudio Sette
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Externí odkaz:
https://doaj.org/article/0b5f01c1d0704f40a6384d79fd934ef2
Autor:
Carmine Carbone, Vincenzo Nasca, Paola Cappello, Maurizio Martini, Claudio Sette, Pietro Delfino, Francesco De Sanctis, Giampaolo Tortora, Vincenzo Corbo, Francesco Spallotta, Geny Piro, Aldo Scarpa, Stefano Ugel, Emilio Bria, Antonio Agostini
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Journal for ImmunoTherapy of Cancer 9 (2021). doi:10.1136/jitc-2021-002876
info:cnr-pdr/source/autori:Carbone C.; Piro G.; Agostini A.; Delfino P.; De Sanctis F.; Nasca V.; Spallotta F.; Sette C.; Martini M.; Ugel S.; Corbo V.; Cappello P.; Bria E.; Scarpa A.; Tortora G./titolo:Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer/doi:10.1136%2Fjitc-2021-002876/rivista:Journal for ImmunoTherapy of Cancer/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume:9
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer 9 (2021). doi:10.1136/jitc-2021-002876
info:cnr-pdr/source/autori:Carbone C.; Piro G.; Agostini A.; Delfino P.; De Sanctis F.; Nasca V.; Spallotta F.; Sette C.; Martini M.; Ugel S.; Corbo V.; Cappello P.; Bria E.; Scarpa A.; Tortora G./titolo:Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer/doi:10.1136%2Fjitc-2021-002876/rivista:Journal for ImmunoTherapy of Cancer/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume:9
Journal for Immunotherapy of Cancer
BackgroundComplex tumor and immune microenvironment render pancreatic ductal adenocarcinoma (PDAC) resistant to immune checkpoint inhibitors (ICIs). Therefore, a strategy to convert the immune hostile into an immunopermissive tumor is required. Recen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d753cb09d5f1267329de321be86b90cc
https://jitc.bmj.com/content/9/9/e002876.full
https://jitc.bmj.com/content/9/9/e002876.full
Autor:
Marta Chiaravalli, Vincenzo Nasca, Giampaolo Tortora, Lisa Salvatore, Carmine Carbone, Vincenzo Corbo, Annachiara Esposito, Geny Piro
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 21, Iss 6386, p 6386 (2020)
International Journal of Molecular Sciences, Vol 21, Iss 6386, p 6386 (2020)
Pancreatic ductal adenocarcinoma is one of the most lethal human cancers. Its precursor lesions include pancreatic intra-epithelial neoplasia, mucinous cystic neoplasm, and intraductal papillary mucinous neoplasm (IPMN). IPMNs usually present as an i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c430d7baa4b2a01e5a30f90796a5f2d4
http://europepmc.org/articles/PMC7504137
http://europepmc.org/articles/PMC7504137